Functional Service Provider (FSP) Model

Building trust and long-term strategic global partnerships

You did an amazing job in such a short time. Thank you very much for your partnership!
Program Lead
Global Pharmaceutical Sponsor

At MMS, our customer-aligned FSP teams go beyond delivery. We partner with you to find the right outsourcing model, level of oversight, scale, and governance to provide a functional sourcing solution that best suits your organization’s unique needs.

Sponsors around the globe engage with MMS as a CRO provider for FSP partnerships in the following areas:

Our FSP models are designed to be flexible and scalable, allowing MMS experts a level of engagement to adapt to your changing needs. Tailored key performance indicators (KPI), governance, and communication plans meet you where you are, as well as provide the tools and structure to achieve your long- and short-term strategic goals.

As an innovative, award-winning CRO, MMS leverages decades of evolving, long-term FSP partnerships with a commitment to process improvement, cost efficiencies, and innovation to help you succeed.

Key benefits of choosing the MMS FSP model include:

  • Experience and consistency of an FSP relationship allows MMS to bring the greatest value and specialized knowledge, rather than other transactional models
  • Effective and efficient communication plans by defining roles and responsibilities, with a clear escalation process
  • Access to global talent ensures seamless resourcing strategies and ability to meet urgent timelines due to regulatory and/or team needs
  • With a focus on innovation and technology, MMS can bring our combined service and technology solutions to build efficient processes and bring time and effort savings
  • Operational efficiencies are gained through interdependent cross-functional services in medical writing, data services, pharmacovigilance, quality control and more
  • Through value-added FSP partnerships, MMS strives for seamless collaborations that build trust

Request more information on our suite of customizable FSP solutions.

Suggested For You

webinar

September 26th, 2024

Regulatory Pathways for Nonprescription Drugs: A Deep Dive into OTC Monograph Reform and FDA Guidance

regulatory intelligence

August 27th, 2024

Recent Guidance on Diversity Action Planning

regulatory intelligence

August 26th, 2024

Oncology Programs at the FDA

regulatory intelligence

August 26th, 2024

Three Key Take Reflections on the Recent Donanemab Approval

webinar

September 12th, 2024

No Stone Unturned: Optimizing the Use of Expedited Pathways and Oncology Center of Excellence Programs to Optimize Drug Development in Oncology

regulatory intelligence

August 9th, 2024

FDA Updates 2024 Language Access Plan

regulatory intelligence

August 3rd, 2024

EMA Launches New Pilot Program for Orphan Medical Devices

perspectives

July 30th, 2024

The Critical Role of Quality Control (QC) – Medical Writing and Beyond

regulatory intelligence

July 26th, 2024

Key Decision Points for Recent Oncology Approvals

regulatory intelligence

July 24th, 2024

Comments Open for Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products

perspectives

July 23rd, 2024

PSI 2024 Ignited Conversations on External Data Sources, Requirements for Estimands, and Bayesian Methodology for Statisticians in Pharma

news

July 17th, 2024

Industry Veteran Ben Dudley Joins MMS as Chief Commercial Officer (CCO) to Drive Continued Growth for the Data-focused Clinical Research Organization